ISLAMABAD – The government of Pakistan has authorised the launch of 35 new medications to address critical health conditions including cancer, hypertension, diabetes, and heart disease. The decision was made public by health officials after a comprehensive review of applications submitted by pharmaceutical firms.
The Drug Regulatory Authority of Pakistan (DRAP) approved every application completed before January 30, 2025, during its 345th Drug Registration Board meeting. The green light applies to both locally manufactured and imported drugs intended for treatment of non-communicable diseases. Approved products include newer treatments for cancers, elevated blood pressure, blood sugar control, renal disorders, and more.
Authorities expect that these approvals will significantly improve access to essential treatments, reduce dependence on smuggled or counterfeit medicines, and support domestic pharmaceutical production. Experts emphasised the importance of strict regulatory oversight to ensure these drugs are used appropriately and only under medical supervision.
Health policymakers and industry representatives noted that the move aligns with broader efforts to strengthen Pakistan’s health infrastructure and address the rising burden of non-communicable diseases among its population. The initiative is seen as a positive stride toward enhancing healthcare delivery and reducing disease-related mortality.
This story has been reported by PakTribune. All rights reserved.
